Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2014

View Archived Issues

Clinical phase I/II results of gene therapy for Becker muscular dystrophy

Phase II clinical results for a three-drug combination against HCV infection

GlaxoSmithKline plans phase II study of GSK-2269557 for acute exacerbation of COPD

New antagonists of S1P3 revert neurodegeneration and neuroinflammation

Nippon Kayaku launches infliximab biosimilar in Japan

Osteopontin RNA aptamer shows potential for the treatment of heart failure

LCZ-696 granted accelerated assessment by CHMP in Europe

Fullerene polyaminocaproic acid tested against HSV infection

Medicines for Malaria Venture collaborates with Cipla and Strides

UCB and Daiichi Sankyo partner to commercialize lacosamide in Japan

Aerocrine plans rights issue to fund commercialization of asthma diagnostic

Bukwang Pharmaceutical acquires Contera Pharma

Fingolimod fails to achieve endpoint in phase III trial in PPMS

Rinat Neuroscience discloses new anti-glucagon receptor antibodies

Incyte patents novel JAK-1 inhibitors

Roche patent reports new anti-HBV compounds

New mu opioid receptor antagonists designed at Dr August Wolff

Suzhou Vivotide Biotechnologies discloses novel VEGFR-1 inhibitors

Dynavax regains rights to DV-1179 under GSK collaboration

Mochida seeks approval in Japan for Lexapro in social anxiety disorder

Janssen files for manufacturing and distribution approval for ibrutinib in Japan

MSD and Kyorin sign Japanese comarketing agreement for desloratadine

EMA accepts for review Imbruvica submission for Waldenstrom's macroglobulinemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...